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Abstract 
 
Awareness and research on epilepsy-related deaths (ERD), in particular Sudden Unexpected Death in 
Epilepsy (SUDEP), have exponentially increased over the last two decades. Most publications have 
focused on guidelines that inform clinicians dealing with these deaths, educating patients, potential 
risk factors and mechanisms. There is a relative paucity of information available for pathologists who 
conduct these autopsies regarding appropriate post-mortem practice and investigations. As we 
move from recognizing SUDEP as the most common form of ERD toward in-depth investigations into 
its causes and prevention, health professionals involved with these autopsies and post-mortem 
procedure must remain fully informed. Systematizing a more comprehensive and consistent practice 
of examining these cases will facilitate 1) more precise determination of cause of death, 2) 
identification of SUDEP for improved epidemiological surveillance (the first step for an intervention 
study), and 3) bio-banking and cell-based research. This article reviews how pathologists and 
healthcare professionals have approached ERD, current practices, logistical problems and areas to 
improve and harmonize. The main neuropathology, cardiac and genetic findings in SUDEP are 
outlined, providing a framework for best practices, integration of clinical, pathologic and molecular 
genetic investigations in SUDEP, and ultimately prevention. 
 
 
List of abbreviations 
 
ERD, Epilepsy-Related Death; FCD, Focal Cortical Dysplasia; GTCS, Generalised tonic-clonic seizure: 
HS, Hippocampal Sclerosis; MCD, Mild malformation of cortical development; SCD, Sudden Cardiac 
Death; SUDEP, Sudden Unexpected Death in Epilepsy; TLE, temporal lobe epilepsy.  
 
Introduction 
 
 
 
Pathologists have long recognised that patients with epilepsy can die suddenly and unexpectedly 
(‘mors subita’) and that following post-mortem we can be ‘none the wiser’ as to the cause of death 
[1]. Indeed, in Sommer’s 1880 seminal post-mortem study of the hippocampus in epilepsy, several 
patients had died suddenly, in some cases associated with a seizure [2]. In the 1980s, Leestma 
commented that although forensic pathologists were well acquainted with seizure-associated 
sudden death, clinical practitioners seemed less aware [3]. Sudden death is now widely recognised 
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by neurologists as a global healthcare concern [4] affecting all age groups with epilepsy [5]. Recent 
estimates suggest the incidence of sudden unexpected death in epilepsy (SUDEP) is around 1 to 1.2 
per 1000 per year in people with epilepsy [6, 7] and there is no indication of a decline.  Indeed, 
Terence et al commented in 1981, that although SUDEP was recognized since 1910 despite all the 
medical advances in treating epilepsy through the last century, as best they could determine the 
frequency had remained unchanged [8]. 
 
Although still a relatively rare event (representing around 0.095% of all deaths), SUDEP accounts for 
approximately 500 of all 1,200 epilepsy related deaths (ERD) per year in the UK [9, 10], often 
affecting young and often otherwise healthy adults. A recent study in San Francisco County found 
that more than half of SUDEP cases may go unrecognized even after retrieval of medical records, 
thorough autopsy and toxicological evaluation, and review by an expert panel of forensic 
pathologists as well as a cardiologist and neurologist [11].  The exact mechanisms of sudden death 
remain unproven in human studies, with hypotheses and theories mainly derived from animal 
experimental studies and anecdotal clinical evidence. SUDEP can occur in many epilepsy syndromes, 
with different seizure types, underlying neuropathology and genetic conditions. It primarily 
associates with generalised tonic-clonic seizures (GTCS) and most often occurs in bed during sleep 
hours with the person found in a prone position (reviewed in [5]). When witnessed and recorded in 
an epilepsy monitoring unit, SUDEP typically followed a GTCS when the obtunded patient 
experiences depressed arousal and respiration, non-tachyarrhythmic cardiac dysfunction, and 
profound depression of cortical EEG activity (postictal generalized EEG suppression, PGES) [12]. For 
such witnessed SUDEP cases an arbitrary cut-off of death within 1 h from acute collapse was 
proposed [13]. 
 
Epilepsy can cause death or contribute to the circumstances of death in numerous ways. Deaths due 
to status epilepticus, complications following seizure such as aspiration pneumonia, injury or 
drowning sustained during a seizure, complications of treatment, or suicide [14, 15] are classified for 
epidemiologic and research purposes as epilepsy-related deaths (ERD). SUDEP is defined as the 
sudden, unexpected death, witnessed or unwitnessed, of a person with epilepsy, where the above 
ERD are excluded and complete post-mortem does not reveal another toxicological or anatomic 
cause of death [13]. Sudden deaths can also occur with symptomatic seizures in patients without an 
epilepsy diagnosis, for example in alcohol withdrawal [11] (Table 1).  Because the diagnosis of SUDEP 
is made by exclusion of other causes of death this therefore requires a clinical history of epilepsy, 
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witness statements and details of the scene and circumstances of death, and complete post-mortem 
examination including toxicology.  
 
Past and current post-mortem practice in epilepsy related deaths 
 
In suspected ERD and SUDEP cases, a ‘complete’ post-mortem examination is generally considered 
to be external and full internal examination, including examination of the whole brain by a 
neuropathologist or personnel with neuropathology training, and toxicology, including 
anticonvulsant levels [16, 17]. National audits of ERD highlighted inadequacy of post-mortem 
investigations in 87% in the UK in 2002 [17] and 41% in a Melbourne study in 2016 [16]. Insufficient 
or absent neuropathological investigations were common and in some regions access to 
neuropathology services is limited.  
 
Recognizing that in some cases autopsies were either not done at all or incomplete (e.g., head only) 
or the cause of death was inconclusive, categories of definite, probable and possible SUDEP were 
devised [18] and subsequently revised [13] to facilitate classification of deaths for purposes of 
epidemiology and research. In ‘probable SUDEP’ cases, circumstances are most consistent with 
SUDEP but post-mortem examinations are lacking or incomplete. In ‘possible SUDEP’ cases, a 
potential competing cause of death (other than epilepsy) is identified, meaning that epilepsy and 
another unrelated cause are both plausible. Cardiac, pulmonary diseases and drug intoxication are 
the most common competing causes in the ‘possible SUDEP’ deaths as well as death in water 
without evidence of submersion or drowning [13].  In instances where the cause of death is 
considered to be the combined effect of epilepsy plus a concomitant condition, the term ‘definite 
SUDEP plus’ has been proposed [13] (Table 1).  
 
Medicolegal aspects and death certification  
 
International and regional autopsy practice in ERD vary and may be conducted by general 
pathologists or forensic pathologists, typically under jurisdiction of a Coroner or Medical Examiner. 
Determining cause of death in ERD cases is a challenge for the Medical Examiner or Coroner since 
they are often confronted with incomplete data (e.g. unwitnessed death, insufficient medical 
history, decomposed body), competing causes of death, or compelling circumstances without 
confirmatory anatomic or toxicological findings.   
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The cause of death is the aetiologically specific disease or injury that initiated the sequence of 
physiologic events leading directly to death. Examples of aetiologically specific causes of death 
include idiopathic epilepsy, atherosclerotic cardiovascular disease, drowning, and blunt force 
trauma. Mechanisms of death, the intervening steps that link the cause to the death, are the altered 
physiology or biochemistry through which the cause exerts its lethal effect and are not aetiologically 
specific (i.e. they can be due to many underlying aetiologies). Because the physiology of organ 
systems is complex and intertwined, there is never just one mechanism. Pulmonary oedema, 
cerebral hypoxia-ischaemia, arrhythmia and seizure are mechanisms of death. Each of these 
mechanisms may be happening during the death of a person with epilepsy. Pulmonary oedema is a 
finding that should be documented when present in ERD but is non-specific and it is recommended 
that this is not used in isolation as the cause of death in a patient with epilepsy.  
Because there is often little evidence at post-mortem examination to determine when a seizure has 
occurred, it is often impossible to be certain that epilepsy was the cause of death in an unwitnessed 
case. When a person with epilepsy dies suddenly and is found to have another potentially lethal 
disease (e.g. Coronary artery disease), the Medical Examiner must weigh which aetiology was the 
more likely cause of death using details from the investigation and post-mortem examination.  
Pulmonary oedema and tongue bites, particularly lateral tongue bites, are considered suggestive but 
not pathognomonic for seizure since they may be due to other aetiologies [19, 20]. Even a 
description of terminal seizure-like activity is not specific since persons dying of other diseases may 
have such activity without established epilepsy. Therefore, medical history and circumstances of 
death are critical to the final evaluation in any case. Absolute certainty of the cause is not needed for 
competent death certification. Once the Medical Examiner or Coroner has explored and excluded 
potential causes unrelated to epilepsy, through detailed investigation and complete post-mortem 
examination, the sudden death of a person with epilepsy is most likely caused by epilepsy.  
The choice of wording for the death certificate varies widely between jurisdictions and between 
individuals within jurisdictions. Inconsistencies and lack of standardisation of wording remain 
widespread [6, 21] limiting our ability to track SUDEP rates over time. Despite the ubiquitous 
reference to SUDEP as a cause of death in the literature, it is an acronym that describes the 
circumstances of death; sudden, in a person with epilepsy, not due to an unnatural cause (e.g. not 
trauma or drowning), not the result of status epilepticus, and in the setting of a negative post-
mortem examination (i.e. no obvious toxicological or other anatomic cause identified) (Nashef, 
1997). Some Medical Examiners and Coroners are resistant to using SUDEP as a cause of death 
statement and favour use of the specific aetiology (epilepsy) instead. Unfortunately, the sudden 
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nature of the death is therefore often omitted from the cause statement, making identification and 
ascertainment of SUDEP cases for epidemiology and research difficult. Nevertheless although rarely 
used in previous decades [22], ‘SUDEP’ is now more commonly recognized as an entity and listed on 
death certificates [23] and accepted as a valid diagnosis [11, 22].  
 
 
Neuropathology in SUDEP: Why it is needed  
 
The primary objectives of the neuropathological examination in an ERD are to (i) exclude any 
unexpected cause of death, (ii) detect any underlying lesion causing the epilepsy and (iii) explore any 
neuropathological consequences of chronic or recent seizure activity. No neuropathological feature 
can establish a seizure as the mechanism of death. Furthermore, epilepsy is a clinical diagnosis 
supported by EEG and there are no specific neuropathological alterations that can categorically 
confirm epilepsy without confirmatory investigations undertaken during life. Neuropathological 
lesions that cause sudden death are often dramatic, macroscopically straightforward diagnoses; 
these include acute traumatic brain injury or spontaneous intracerebral haemorrhages [24]. More 
focal or subtle neuropathologies, such as fatal colloid cysts [25] or acute encephalitis [26, 27], 
require a systematic, careful approach to brain examination with confirmatory 
immunohistochemistry or molecular studies, for example for viral markers, if necessary.  
 
Among lesions that cause epilepsy, published series do not suggest that any single type is over-
represented in SUDEP (Table 2, Figure 2). The range of pathologies encompass those commonly 
encountered in surgical epilepsy series, including hippocampal sclerosis, cortical malformations such 
as focal cortical dysplasia (FCD) and low grade tumours [28]. Focal neuropathological abnormalities 
occur in ~50% of SUDEP autopsies ranging from 34 to 89% between larger SUDEP series (Table 2). 
Leestma, identified brain lesions in 60% of SUDEP cases compared to 11% in non-epilepsy autopsies 
[3], but not all SUDEP studies support this [23, 29] and there are few post-mortem non-SUDEP 
epilepsy studies for comparison (Figure 2). The variability in lesion detection may reflect the 
population demographics of the study as well as methodological differences between studies (e.g., 
macroscopically visible versus additional histological pathologies being reported). Identification of 
brain pathology pertaining to epilepsy is highly dependent on (i) the brain being examined in detail 
following a period of fixation [3, 30, 31], (ii) the number of histological regional samples taken [31], 
(iii) the level of scrutiny, for example if routine immunohistochemistry was carried out, as 
recommended in epilepsy surgical diagnostic protocols, [32], and (iv) the experience and training of 
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the pathologist. In the forensic setting, the depth and detail of neuropathological investigation may 
be negatively affected by limited resources, including cost and access to special histologic 
techniques, neuropathology services and reporting time restrictions. Indeed, many epilepsy related 
pathologies are focal and visible only microscopically, some requiring specific immunohistochemistry 
to confirm diagnosis. Examples include milder or atypical forms of hippocampal sclerosis (ILAE type 
3), granule cell dispersion [33] and hippocampal mossy fibre sprouting, considered to be a relatively 
specific secondary process in epilepsy (reviewed in [34]) (Figure 1c,d). Mild malformations of cortical 
development (MCD), in particular mild MCD type II (heterotopic neurones in the white matter), have 
been reported in SUDEP  [35] but are recognised to require quantitative immunohistochemistry 
confirmation with comparison to validated control ranges [36]. Currently we lack international 
agreement on precise diagnostic criteria for Mild MCD type II in surgical TLE or other brain regions 
[37] and because of this its recognition and reporting in ERD may widely vary.  Even well-defined 
epileptogenic pathologies likely go undetected at post-mortem examination due to under-sampling. 
For example, symptomatic FCD are not infrequently MRI ‘occult’ even with modern neuroimaging 
[38] (Figure 1e,f); such lesions are typically macroscopically less visible with absent hallmark 
features, as regions of cortical thickening or blurring of the grey-white matter interface [37].  Access 
to clinical notes and any localising investigations (e.g. EEG, seizure semiology, MRI, PET findings) is 
good practice and may help to focus the pathologist on the epileptogenic zone and anecdotally can 
aid in the identification of underlying pathology, although data is lacking to prove  this increases 
overall lesion detection rate. Given these methodological approaches that may influence the 
sensitivity of the post-mortem, there is lack of clarity from the available neuropathological series as 
to whether structural brain lesions are more frequent in SUDEP than epilepsy without SUDEP and 
therefore if symptomatic epilepsy compared to idiopathic/genetic causes represents a higher risk.  
 
 
Regional Neuropathology - insights into mechanisms in SUDEP 
 
Repetitive seizures can initiate molecular signals and cellular processes that ultimately alter the 
brain structure in terms of neuronal loss, gliosis [39], microgliosis and inflammation [40], blood brain 
barrier breakdown [41], vascular changes and axonal reorganisation [42, 43]. These can occur in the 
area of seizure onset in focal epilepsies but widespread brain alterations in the cortex [44], thalamus 
and cerebellum can be observed at post-mortem [45]. Many of these sequelae represent a 
‘pathological’ repair process that can further alter the seizure threshold, as exemplified by 
astrogliosis [39]. One key question is whether specific or strategic patterns of epilepsy-related brain 
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injury occur in SUDEP which could increase vulnerability or mechanistically be relevant to the cause 
of death. Central autonomic networks and cardiorespiratory centres are obvious candidate areas to 
investigate [12, 46]. These include the insular cortex, prefrontal cortex, hippocampus and amygdala 
through their connections to the hypothalamus, pons and medulla [47]. Ictal autonomic phenomena, 
as urinary urge, piloerection, and heart rate changes arise due to excitation or inhibition of these 
brain regions and are particularly associated with limbic or TLE [48]. Neuropathology studies have 
focused on chronic structural alteration as well as acute pathology. Inherent caveats to SUDEP 
research include imprecise times of death as most are unwitnessed, the unanticipated nature of 
death that incurs logistical delays in brain removal, and lack of suitable controls groups such as non-
epilepsy sudden deaths and non-SUDEP epilepsy cases of similar age and severity of epilepsy. 
 
Brainstem: Central control of respiration is regulated by interconnected medullary nuclear groups 
forming the ventral respiratory column [46] including the Bötzinger and pre-Bötzinger complex [49] 
and modulated by other brainstem networks including the medullary raphe [50]. Notably, in 
experimental models of SUDEP, cortical seizures initiated spreading depolarisations or ictal activity 
in these brainstem regions which resulted in cardiorespiratory arrest [51, 52].  In neurodegenerative 
conditions with accompanying central respiratory deficits, selective reduction of specific respiratory 
(somatostatin/neurokinin 1Receptor+) nuclear groups occurs [53], and in Sudden Infant Death 
Syndrome (SIDS), alterations to the medullary serotonergic neurones is observed [54].  In MRI 
studies, medullary volume loss, proposed to be secondary to sustained seizure propagation, is of 
potential relevance to ictal autonomic disturbances in SUDEP [55] but there are limited 
neuropathology studies investigating specific cellular alterations  [56, 57].  
 
Amygdala: In TLE amygdala neuronal loss or sclerosis is variably present [58, 59]. Seizure spread or 
stimulation of the basolateral and lateral nucleus amygdala results in transient apnoea [60, 61], the 
central nucleus of the amygdala being connected to brainstem cardio-respiratory and other 
autonomic nuclei; therefore, underlying amygdala pathology could be mechanistically relevant in 
SUDEP. A stereological study of the lateral nucleus of the amygdala confirmed significantly reduced 
neuronal density and higher astrocytic densities in SUDEP compared to non-epilepsy controls (Figure 
1i,j) [62]; this was more prominent in the left side and independent of hippocampal sclerosis but no 
significant alteration in the central nucleus was found.   MRI studies in SUDEP show higher amygdala 
volumes on the right side compared to control [63]. A more recent pathology study, however, failed 
to confirm significant differences in density of GFAP+ astroglia in the lateral, basal and accessory 
basal nucleus of the amygdala in SUDEP compared to controls [56].  
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Hippocampus:  There is no evidence that hippocampal sclerosis is more prevalent in SUDEP. HS is 
reported in up to 21% of 145 SUDEP cases [31] ((Table 2, Figure 2), compared to 30.5% of 650 [64] 
and 45% of 235 epilepsy post mortems [65].  Some unexplained deaths in infancy and childhood may 
be seizure-related and unexpected deaths in young patients with febrile seizures may share similar 
pathogenetic mechanisms to SUDEP [66, 67].  Developmental lesions of the dentate gyrus of the 
hippocampus have been reported in SIDS including varying degrees of bi-lamination of the dentate 
gyrus, noted in 41% of 153 cases [68]. Similarly, hippocampal abnormalities, including excessive 
convolutions of the dentate gyrus, granule cell bilamination, folding of the subiculum, and 
hippocampal malrotation were associated with sudden death in children (>1 year old) with a history 
of febrile seizures [69, 70]. Hippocampal malrotation is a developmental anatomical variant, 
identified in 23% of the general population on MRI in one series and more commonly left sided [71]. 
Malrotation of the hippocampus was found on MRI in 8.8% of patients with febrile status in the 
FEBSTAT study [72] with predilection for the left side, compared to 2.1% in their control groups [73]. 
Hippocampal malrotation may represent a substrate to febrile seizure and epilepsy [74] and granule 
cell dispersion is postulated as a morphological biomarker in SIDS that could indicate impaired 
connectivity between the hippocampus and brainstem [68] or a manifestation of previous 
unrecognised ictal activity [75].  Granule cell dispersion, a common and often prominent feature in 
approximately 40% of adult TLE patients with hippocampal sclerosis [34], was reported in only 4% of 
145 SUDEP cases without sclerosis [31]. However, as no study has systematically evaluated SUDEP 
cases comparable to SIDS [68-70] or surgical studies [76], this feature may be under-recognised. 
Similarly, hippocampal malrotation of varying degrees occur in 9.7% of SUDEP cases independently 
of sclerosis, which was more common on the left side [31]. In a quantitative MRI study, increased 
hippocampal volumes in SUDEP were noted on the right side [63]. More systematic analysis of 
hippocampal pathology and any lateralisation is warranted in SUDEP to explore 
structural/developmental alterations predisposing to SUDEP as a surrogate biomarker.  
Thalamus: A reduction of grey matter volume in the posterior thalamus was noted in SUDEP on 
quantitative MRI which is of potential significance as this region has roles in breathing inhibition 
following episodes of hypoxia [63]. Involvement of the posterior thalamus in seizure initiation and 
cardiovascular modulation [77] and altered connectivity between thalamus, brainstem and frontal 
cortex may be relevant in some patients at high risk for SUDEP [78]. In post-mortem studies, the 
severity of thalamic pathology, based on reduced synaptophysin immunolabelling and gliosis, 
correlates with duration of seizures [79] but regional patterns of thalamic vulnerability in SUDEP, 
including any predilection for pulvinar or posterior lobe, remains to be addressed.  
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Cerebellum: Macroscopic atrophy or selective Purkinje cell loss were reported in 29% and 12% of 
SUDEP subjects respectively [31] but in up to 57% of other SUDEP series [80]. By comparison In vivo 
MRI findings showed cerebellar atrophy in 22% to 36% of non-SUDEP epilepsy groups on MRI 
measurements [81]. The fastigial nucleus of the cerebellum in functional imaging studies has roles in 
normal autonomic regulation of baroreflexes [82]. Cerebellar damage has been implicated in SUDEP 
[83] but requires more rigorous pathology and molecular assessment in order to identify its role in 
the pathogenesis of SUDEP.  
Cerebral cortex :  Left insular cortex damage has been reported in SUDEP and associated with 
autonomic instability [84] and is a candidate region for further study[85], but the mechanisms by 
which these anatomical abnormalities relate to sudden death are unclear. Apart from 
documentation of acute neuronal changes (see below) in the insula, there are no neuropathological 
correlative studies. 
 
SUDEP – evidence for acute brain injury 
 
SUDEP may be the consequence of extensive, irreversible neuronal damage during a seizure, 
strategic injury in critical autonomic regions or the cumulative effects of recent poor seizure control 
[86]. Such cellular injury or neurochemical exhaustion could decompensate normal homeostatic, 
auto-resuscitative mechanisms following a fatal seizure. Acute eosinophilic neuronal change has 
been reported in up to half of SUDEP cases [31], although with notable differences between series 
(Table 2) which may reflect to its varying extent and hence detection (Figure 2). It primarily involves 
the hippocampus (CA1/subiculum) although widespread involvement including cortical laminar 
patterns can occur [35]. This non-specific cytopathic change likely reflects hypoxic and/or excitotoxic 
cellular stresses occurring acutely (rather than immediately) in the last six hours. Hypoxia in epilepsy 
reflects ictal hypoperfusion [87], impaired central respiration/transient apnoea, external airway 
compromise during seizure or a synergistic interaction of these.  Acute neuronal injury in SDUEP was 
significantly more frequent when seizure episodes occurred in the 24 h prior to death, the body was 
found in a prone position, external airways were obstructed, or brain swelling was present [31]. In 
sudden unexplained death in childhood, hyper-eosinophilic acute ischaemic neurones were 
identified at similar rates to controls groups with known cause of death [69]. 
 
Investigations in SUDEP of markers of acute neuronal death  (necrosis, apoptosis) or reversible 
injury, including cell-stress signals promoting neuronal survival (VEGF, JNK1-3 , BNDF) [88], enable 
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more objective data regarding the type, severity and distribution of brain injury, and could aid in 
localising the epileptogenic zone and explore secondary effects of ictal discharges involving central 
autonomic networks [48]. Heat Shock Protein (HSP-70)-positive neurones in all hippocampal 
subfields were more frequent in SUDEP compared to non-epilepsy and other epilepsy sudden 
deaths; similar differences were not noted for c-JUN neuronal expression [57]. Labelling of insular 
cortex and brainstem nuclei with HSP-70 and c-JUN was also observed [57]. Hippocampal neuronal 
hypoxia-inducible factor 1-alpha (HIF1-α) and vascular endothelial growth factor (VEGF) expression, 
both upregulated in response to hypoxia, occur in SUDEP although did not significantly differ from 
control groups [89]. A more recent study identified fewer HIF1-α neurones in the parahippocampal 
gyrus in SUDEP compared to non-epilepsy sudden death controls but no differences in the 
hippocampus, amygdala or brainstem, where neurones in the pre-Bötzinger complex were labelled 
strongly [56]. Further investigations correlating evidence of neuronal injury with clinical and genetic 
variables and circumstantial evidence of death will be important to inform on mechanisms in SUDEP.  
 
Seizure induced neuroinflammation [40] and acute blood brain barrier dysfunction [41] pose obvious 
candidate mechanisms in SUDEP. Increased, but statistically non-significant, brain weights and brain 
swelling, likely due to acute cerebral oedema, occur in SUDEP (Table 2) [31]. However, studies as yet 
do not indicate significant neuroinflammation in SUDEP; less lymphocytic inflammation was noted 
than controls [80] and quantitative analysis of HLA-DR activated microglia in the hippocampus, 
amygdala and medulla did not differ between SUDEP, and non-epilepsy sudden deaths [56] (Figure 
1g, h). Albumin and IgG, tissue markers of acute blood brain barrier breakdown, showed less 
labelling in SUDEP in the parahippocampal gyrus, and fewer CD163-positive peripheral macrophages 
(indicative of increased vascular leakage) were found in the ventrolateral medulla [56]. In summary 
is unclear if neuroinflammation, or its cumulative effects in the presence of repeated seizures, is 
related to the pathogenesis of SUDEP. 
 
 
Cardiopulmonary pathology and investigations in SUDEP 
 
Pulmonary pathology is a common autopsy finding in SUDEP (Table 2) reported in 72% of cases, with 
the most frequent findings being pulmonary congestion or oedema [90]. Although the incidence of 
post-ictal pulmonary oedema has been debated [91], radiographic evidence  was reported in 29% of 
patients following GTCS [92]. The pathogenic mechanisms of oedema following GTCS are not 
understood, and include increased sympathetic drive, mediated by the medulla and hypothalamus, 
altered hydrostatic pressures and increased pulmonary capillary permeability (‘neurogenic 
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pulmonary oedema’) [91]. In SUDEP, additional exacerbating factors include central respiratory 
inhibition and cardiogenic and haemodynamic dysfunction. 
 
Cardiac examination in ERD and SUDEP is essential to exclude cardiac causes of death such as 
undiagnosed myocardial disease, valve disease, coronary artery disease or structural abnormalities 
of the conduction system.  When the clinical diagnosis of epilepsy is less certain and the cause of 
death is considered likely cardiac, but no lesion is identified, sampling for histology is required with 
mapped blocks of anterior, lateral and posterior right and left ventricle and septum from a 
representative mid-ventricular transverse slice and right ventricular outflow tract. In addition blocks 
from conduction tissue is taken if history of conduction defect is recorded clinically.  In some 
situations, fixation of the heart and referral to a specialist cardiac pathologist is recommended  as 
best practice and the organ can be returned following examination. There should be a low threshold 
for sending the whole heart to a specialist centre for expert opinion, at the discretion of the 
pathologist and Coroner or Medical examiner and discussion with the family (for UK guidance see 
https://www.rcpath.org/profession/clinical-effectiveness/clinical-guidelines/autopsy-
guidelines.html). Following status epilepticus or a convulsive seizure, stress-induced cardiac changes 
or Takotsubo cardiomyopathy can occur [90] (Figure 3). When mild to moderate cardiac pathology is 
found in a case with circumstances and clinical features suggestive of SUDEP, the classification 
should be ‘definite SUDEP plus’ if the cardiac condition could be a contributing cause, or ‘possible 
SUDEP’ if the cardiac condition is a competing cause of death.  This nuanced distinction, often 
challenging to apply in specific cases, was introduced in the more recent SUDEP classification [13]. 
For example, if a 30-year-old man with treatment resistant nocturnal convulsions is found dead in 
bed in the morning in the prone position with a tongue laceration, and post-mortem shows a 40% 
occlusion of the left anterior coronary artery or mild cardiomegaly, the cause of death is likely 
epilepsy, although the cardiac pathology may have contributed (definite SUDEP Plus).   By contrast, a 
55-year-old woman with infrequent seizures who dies alone in her flat during the daytime with no 
evidence of a seizure and who is found to have moderate cardiomegaly with left ventricular 
hypertrophy could have died from the cardiac disease or epilepsy (possible SUDEP).  
Subtle cardiac pathologies reported in SUDEP series include myocyte hypertrophy and mild 
interstitial fibrosis (Figure 3) (Table 2 and reviewed in [90]). It remains unclear whether these 
changes represent a sequel of seizures or antiepileptic drugs, or may be similar to baseline rates of 
cardiac pathology in other non-cardiac sudden deaths; their relevance to the mechanism of SUDEP is 
unknown. Nevertheless, this again suggests that routine systematic histological examination of the 
myocardium, even in what appear to be typical SUDEP cases [93], is warranted in to monitor the 
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significance of these unexpected findings. Ictal disturbance in cardiac electrophysiology that induces 
dysrhythmias has long been considered a candidate mechanism of death in SUDEP [94]. Further, 
several ion channels have shared expression in brain and heart and cardiac genes associated with 
long QT syndrome (LQT), bradycardia, and SCD (KCNQ1, KCNH2, SCN5A, RYR2, HCN4) can cause both 
epilepsy and arrhythmias or increase the risk of seizure-induced arrhythmias and have been linked 
to SUDEP (reviewed in [5] and see section below) (Table 3).  
 
 
Genetics of SUDEP and the molecular autopsy  
 
 
In cases where the scene investigation, autopsy and toxicological studies do not reveal a probable or 
definite cause of death, post-mortem genetic testing can reveal a variant or mutation that could 
cause sudden death.  These ‘molecular autopsies’ emerged from studies in which sudden cardiac 
death was suspected but only confirmed when post-mortem DNA analysis revealed genetic findings 
that established the likely mechanism of death.  De novo or known pathogenic mutations in cardiac 
channelopathy or cardiomyopathy genes were found in 27% of children and young adults with 
unexplained sudden cardiac death [95].   While molecular autopsy is well established in evaluating 
cases of suspected sudden cardiac death, its role in defining the mechanism of death in epilepsy 
patients remains less well defined. Unlike sudden cardiac death, where pathogenic variants in genes 
that modulate the cardiac rhythm and myocardium are associated with sudden death and have a 
well-characterized lethal mechanism, defining a SUDEP gene is more challenging.  In the largest 
study to date, 61 SUDEP cases underwent post-mortem whole exome sequencing. The investigators 
identified mutations in cardiac arrhythmia (all long QT) genes (7%), candidate pathogenic variants in 
dominant cardiac arrhythmia genes (15%) and mutations or candidate pathogenic variants in 
dominant epilepsy genes in 25% [96].  The unanswered question is the potential pathogenic 
relationship and role of these mutations in SUDEP.  
 
Some genetic mutations are associated with an increased risk of SUDEP in humans and in some 
animal models of SUDEP.  However, most of these mutations are established causes of epilepsy that 
are often treatment-resistant and associated with frequent GTCS (e.g., SCN1A, SCN8A, DEPDC5, 
dup15q; Table 3).  The epileptic encephalopathies are associated with high rates of sudden death 
and status epilepticus [97].  In Dravet syndrome [98], the mortality rate/1000-person-years was 15.8 
and SUDEP rate was 9.3/1000-person-years. These rates are more than 10-fold higher than other 
paediatric epilepsies but similar to cohorts of adults with refractory epilepsy being evaluated for 
surgery (6-9/1000-person-years) [99]. 
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The association of these genes with SUDEP could result solely from their role in causing severe 
epilepsy with frequent convulsive seizures and status epilepticus (e.g., SCN1A, SCN8A, dup15q) or 
epilepsy of variable severity (e.g., DEPDC5). However, specific genetic mutations may also 
independently contribute to the mechanism of death by facilitating autonomic instability, cardiac or 
respiratory dysfunction, or more prolonged postictal depression of arousal following a seizure or 
interfering with post-ictal autonomic recovery.  Experimental models of Dravet syndrome reveal 
parasympathetic hyperactivity accompanies SUDEP and death can be prevented by parasympathetic 
blockade [100].  The relevance of this to human Dravet patients is uncertain as we lack autonomic 
data related to SUDEP, Dravet syndrome, and the broader epilepsy population.   Marked 
sympathetic hyperactivity (elevated electrodermal activity) was documented post-ictally in a 20-
year-old SUDEP case (Picard et al 2017 Neurology In press).  Sympathetic hyperactivity is well 
documented after most GTCSs in animals and humans.  The mechanism of death in SUDEP may be 
related to postictal abnormalities of both parasympathetic [101] (e.g., bradycardia, hypotension) and 
sympathetic systems [5]. 
 
The challenges in linking an epilepsy gene to SUDEP are highlighted by DEPDC5.  This gene codes for 
a member of the IML1 protein family involved in G-protein signalling networks. The protein coded by 
DEPDC5 is a component of the GATOR1 complex that inhibits the mTORC1 pathway and can cause 
autosomal dominant familial focal epilepsy of variable severity.  Pathogenic variants of DEPDC5 were 
enriched in the largest genetic study of a SUDEP cohort [96].  In a series of 61 SUDEP cases, five 
cases had DEPDC5 variants; three were nonsense mutations that were very likely pathogenic while 
two were missense variants, one of which is highly conserved in evolution.  Yet DEDPC5 is the most 
common gene associated with familial focal epilepsy and is a common gene for sporadic focal 
epilepsy [102].  The challenges of differentiating genetic from other factors in the mechanism of 
death is exemplified by the two brothers with DEPDC5 mutations who both died from SUDEP but 
both had histories of AED nonadherence [103]. Since DEPDC5 patients often have frontal lobe foci 
and frontal lobe deficits, this can potentially impair planning and judgement, and this gene may 
increase SUDEP risk by causing treatment-resistant epilepsy as well as increasing the risk of life-style 
factors such as sleep deprivation, medication nonadherence and excess alcohol use.  
 
SUDEP is not limited to treatment resistant epilepsies.  SUDEP rarely complicates benign epilepsy of 
childhood with centrotemporal spikes and a history of convulsions not treated with antiepileptic 
drugs [104]. Further, one third of young children who die suddenly and have unrevealing 
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comprehensive death investigation, have a history of febrile seizures (ten-fold greater than the 
general population), suggesting seizure as a mechanism of death [67]. Thus, any patient with 
seizures is likely at increased risk for SUDEP post-ictally.  Larger genetic studies are needed 
comparing SUDEP cases and control epilepsy populations matched for epilepsy severity, to 
determine if epilepsy genes increase SUDEP risk beyond the increased risk related to epilepsy 
severity.    
 
As detailed above SUDEP is also associated with variants and mutations of neuro-cardiac 
channelopathy genes.  The presence of LQT gene mutations in SUDEP suggests that a seizure could 
provoke a lethal cardiac arrhythmia, or sudden cardiac death could occur independently of a seizure.  
Both possibilities may occur in some cases, although the available literature on deaths recorded in 
epilepsy monitoring units do not identify a single case where a seizure led to lethal arrhythmia or 
where a lethal arrhythmia spontaneously occurred [12].  However, several near-SUDEP cases had 
arrhythmias and it is possible that patients with LQT gene mutations and epilepsy have treatment-
responsive epilepsy and are rarely admitted to epilepsy monitoring units. Further, the extensive 
literature on cardiac changes during and after seizures recorded in epilepsy monitoring units very 
rarely identifies potentially lethal seizure-induced cardiac arrhythmias [94, 105, 106].  The most 
serious cardiac rhythm changes associated with seizures are ictal asystole, atrial fibrillation, and ST-
wave depression. These are less often associated with mutations in cardiac genes than torsade des 
pointes ventricular tachyarrhythmias. However, abnormalities in cardiac repolarization on ECG are 
more frequent in SUDEP than control epilepsy cases [107], suggesting a potential role of cardiac 
gene variants in SUDEP.  As noted above, pathogenic and rare variants of cardiac channel genes are 
found in SUDEP cases [108].  Moreover, all channelopathy genes are expressed to some extent in the 
brain, including the brainstem.  Thus, if these cardiac channelopathy genetic variants increase SUDEP 
risk, they could do so by alterations in the heart or brain, or both organs. The extremely rare 
occurrence of ventricular tachyarrhythmias in recorded SUDEP cases, or during seizures recorded in 
epilepsy monitoring units, suggest that if cardiac channel genes contribute to SUDEP pathogenesis, it 
may be via a different mechanism than their role in sudden cardiac death.  Finally, some or many 
variants in cardiac genes may be unrelated to SUDEP pathogenesis.   
 
 
The future and biobanking in SUDEP 
There is current momentum from professional groups, as well as patient support groups, to move 
from mere recognition and documentation of SUDEP to identifying its causes and preventing its 
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occurrence [109]. Despite an initial ‘head start’ by pathologists in recognising SUDEP, human tissue 
and cell based research programmes in ERD have somewhat lagged behind. The reasons are complex 
and manifold: (i) lack of clinical recognition and importance of the problem to allocate proportionate 
research funding in this area, (ii) establishing research collections in forensic setting where priorities 
and human tissue legislation is primarily geared toward establishing cause of death, with limited or 
restricted capacity to interact with research programmes, (iii) problems obtaining consent from 
immediately bereaved families, (iv) lack of easy access to a local or referral neuropathology services 
in some regions [16], (v) problems with post-mortem decomposition of autopsy tissues [80] with 
many epilepsy research programmes focussing resources on optimally preserved surgical tissues, (vi) 
lack of sufficient numbers of suitable control cases and tissues, (vii) lack of standardised guidance 
documents for conducting SUDEP autopsies, the core practice of which can vary between regions 
and jurisdictions. This last point is pertinent, as despite a flurry of clinical practice documents on 
SUDEP aimed at neurologists and health care professionals (14 from the first half of 2017 alone [6, 7, 
9, 110-120] there are very few directed at the pathologist regarding the elements and scope of the 
post-mortem examination. There are no consensus international best practice guidelines (in contrast 
to surgical epilepsy neuropathology practice [32, 33, 37] and informal enquiry indicates that very 
few countries have any form of autopsy guidelines for investigations in ERD. In the UK guidance 
documents for the approach to post-mortem examination, tissue sampling protocols (Figure 1 ; 
Table 4) and classification of cause of death in suspected epilepsy and sudden cardiac cases are 
issued by the Royal College of Pathologists series (https://www.rcpath.org/profession/clinical-
effectiveness/clinical-guidelines/autopsy-guidelines.html) ; these provide guidelines and do not 
mandate practice and are based on current evidence available in ERD and SUDEP.  
 
In establishing the Centres for SUDEP research [121], the extent of the logistical problems and 
existing barriers to biobanking in ERD and SUDEP became apparent. These obstacles need to be 
addressed in the future and invested in to accelerate research into this condition. All biobanking 
should be conducted in full agreement with Coroners and Medical Examiners and following 
discussion and informed consent of the families (Figure 4). Local practical and economical strategies 
to more accurately determine the cause of death in ERD should utilise regional expertise in neuro 
and cardiac pathology to augment the investigation with timely and detailed reports (Figure 4). Post-
mortem imaging, including MRI, CT and angiography is likely to play an increasing role in sudden 
death examination [122, 123], where it may supplement standard autopsy procedures by revealing 
lesions difficult to assess by macroscopic examination. There is no published study applying post-
mortem imaging in ERD, however, high resolution MRI of whole brains or regions provides more 
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detailed information of structural brain abnormalities enabling correlation with histological findings 
as ongoing areas of research [124, 125]. Prospective collection of DNA from brain, heart and lungs 
could also expand the range and scope of investigations.  Techniques such as single cell RNAseq, 
proteomics usually requiring fresh frozen tissue, will provide complementary data on gene 
expression  ;  however, with newer technologies these methods are feasible with even formalin 
fixed, paraffin-embedded (FFPE) [126]. Greater availability of bio-specimens could facilitate 
numerous studies, including 1) systematic comparison of DNA exomes derived from blood and brain 
to examine the role of possible somatic mutations, 2) brainstem RNAseq in areas of interest (e.g., 
medullary raphe and pre-Bötzinger nuclei), 3) detailed examination of the cardiac conduction 
system.  Such systematic tissue biobanking may enable better stratification of cause of death in 
SUDEP through integrated clinical, imaging, pathological and molecular diagnosis (Figure 4).  
In summary, the evidence indicates that SUDEP is a heterogeneous condition in terms of both the 
underlying epilepsy neuropathology, genetics as well as mechanism of death. SUDEP at present 
provides a convenient ‘umbrella’ term under which to collect, stratify and further investigate these 
cases to shed light on any divergent or convergent pathogenetic mechanisms.  Hopefully, in the 
future, epilepsy centres, neuropathologists, cardiac pathologists and medical examiners, coroner 
offices, and government funding agencies will collaborate in establishing international 
biorepositories to advance SUDEP research.  
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Figure legends 
 
Figure 1. Neuropathology in SUDEP and sampling protocols 
A and B. Neuropathology block sampling protocols and findings in SUDEP. Recommended sampling 
strategy includes the frontal watershed regions (1), temporal cortex (2), amygdala (3), thalamus (4) 
hippocampus from both sides and at several levels if indicated (5) and insular cortex with basal 
ganglia (6); see Table 4 for details of coronal levels and other recommended or essential samples as 
part of the routine neuropathology examination.  C:  Mild granule cell dispersion in SUDEP case.  E. 
Mossy fibre sprouting in the hippocampus with ZnT3 immunostaining in SUDEP E: Temporal lobe 
cortex from a patient with a SUDEP. Macroscopic examination of the brain was unremarkable but 
samples from the left hemisphere showed regions of focal cortical dysplasia type IIA. This was 
confirmed with immunohistochemistry for neurofilament (shown in F). G, H. Study of 
neuroinflammation in SUDEP [56] ; No significant increase in HLADR expressing microglia in 
hippocampal subfields in SUDEP (G) compared to non-epilepsy sudden deaths (H). I, J. Studies of 
chronic alterations in SUDEP: The lateral nucleus of the amygdala showing increased gliosis in 
SUDEP (I) compared to non-epilepsy control (J), shown in one study on stereology [57] , which could 
be relevant to altered function of this nucleus. Bar in G equivalent to 75 microns for G – J; C, D & F 
taken with x 20 objective and E with x 20 objective.  
 
Figure 2. Scatter graph of relative frequency of neuropathology lesions reported in SUDEP series.  
Red triangles represent data from reported series (as detailed in Table 2) and the black line is the 
average for all SUDEP series. ‘Inflammatory’ in this context refers to inflammatory diagnosis at 
autopsy as meningoencephalitis. This is compared to data from epilepsy PM series (*these also 
include some SUDEP cases) (Green triangle) [65, 127]and to surgical series (Blue triangle; data from 
the European Epilepsy Brain Bank of over 3,000 cases).  
 
Figure 3. Cardiac pathology and sampling in ERD and SUDEP 
A. . Mild myocardial hypertrophy in a sudden death case. B. Takotsubu cardiomyopathic changes 
with several myocytes showed an increased band of eosinophil staining and early contraction band 
formation (arrows). Bar = 50 microns.  
 
Figure 4. Future approaches in ERD.  
Vision of future post-mortem examinations in epilepsy related deaths with intergrated clinical-
pathology-genetics classifications and stratification of cause of death and intergration with research 
biobanks.  *A SUDEP gene could be defined as a gene mutation of pathogenic variant that causes 
epilepsy and increases the SUDEP risk via the central or peripheral nervous system or end-organ 
effects on respiratory, cardiac or other autonomic functions [5]. ~ Some post-mortem investigations 
would be carried out as relevant on a case by case basis. COD= cause of death, SCD = sudden cardiac 
death 
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Category of 
sudden death 
Definition / criteria Post mortem findings pertaining to 
cause of death 
DEFINITE 
SUDEP 
Sudden, unexpected, witnessed or 
unwitnessed. 
Exclude traumatic causes and 
drowning (death in ‘benign’ 
circumstances). 
Clinical diagnosis of epilepsy*. 
Status epilepticus cases excluded 
(seizure ≥ 30 min or serial seizures 
without recovery between). 
No cause of death identified (including 
toxicology, histology and 
neuropathology examination). 
DEFINITE 
SUDEP PLUS 
Criteria as for Definite SUDEP. Concomitant condition identified: not 
proven to be the cause of death but 
may have contributed. 
PROBABLE 
SUDEP 
Criteria as for Definite SUDEP. Not conducted or 
Elements of the examination 
incomplete (e.g. no neuropathology or 
toxicology screen). 
POSSIBLE 
SUDEP 
Criteria as for Definite SUDEP. A competing cause of death is 
identified at post-mortem examination. 
SUDDEN 
DEATH WITH 
SYMPTOMATIC 
SEIZURE 
Clinical diagnosis of epilepsy lacking* 
(e.g. alcohol withdrawal seizures). 
Pathology relating to underlying 
condition may be found. 
Table 1. Categories of Sudden Death in Epilepsy (adapted from [11, 13]). * Epilepsy defined as ≥ 2 
unprovoked seizures at least 24 hours apart or a single unprovoked seizure with an enduring risk for 
further seizures.  
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AUTHOR PERIOD OF 
STUDY 
REGION, 
COUNTRY 
NUMBER  
SUDEP 
(AGE 
RANGES) 
TYPE OF 
STUDY 
NEUROPATHOLOGY 
(number (%) of cases with 
structural lesions/pathology) 
 
PULMONARY 
PATHOLOGY 
CARDIAC 
PATHOLOGY 
KROHN[1] 10 years 
circa 1963 
Oslo,  
Norway 
14 
(10-70 ys) 
Retrospective 5/14 (36%) : atrophic/senile 
atrophy, slight 
meningoencephalitis, seizure-
related change, NOS 
No detail No detail 
TERRENCE[8] 1978-1979 Pittsburgh, 
USA 
8 
 (9-31ys) 
Retrospective 3/8 (38%); cerebral oedema 2/8 
(25%), old TBI 1/8 (12%). Acute 
neuronal injury in hippocampus 
and cerebellum also described.  
(100%) Pulmonary 
oedema  
No detail 
LEESTMA[3] 1976-1979 Cook 
 County,  
USA 
66 
 (10 
months -60 
ys) 
Retrospective 46/66 (60%): Old 
TBI/contusions (26%), tumours 
(4.5%), HS (6%), MCD (6%), 
scars (9%), old CVA (3%) 
atrophy/hemiatrophy (7.5%), 
TS (1.5%) cerebral oedema 
(12%) 
19/66 (29%) 
Pulmonary 
oedema/congestion 
 No detail 
LEESTMA[128] 1983 Cook  
County, 
USA 
60 
 (8 month - 
83 ys) 
Prospective 24/60 (40%): contusions (11%), 
scars (20%), old CVA (17%), HS 
(12%), cerebellar atrophy (7%), 
MCD (7%), VM (2%) tumour 
(2%) 
(42/52) 80% 
Pulmonary oedema 
(9/60) 15%  Mild 
to moderate 
atherosclerosis 
 2/60 (3%) 
myocardial 
fibrosis  
EARNEST[129] 1982-1987 Denver 
County,  
USA 
44  
(3-58 ys) 
Retrospective 
Review, PM 
Findings 
15/44 (34%): 14/44 (31.8%) 
cerebral oedema but no 
herniation 
38/44 (86.4%) 
Pulmonary 
congestion/oedema  
5/44 (11%) focal 
interstitial 
fibrosis  
NATELSON[130] 1998 Morris 
County,  
USA 
7  
 (12-44 ys) 
Case Control 
Study 
1/7 (14%): communicating 
hydrocephalus 
no detail 5/6 (83%) 
myocyte 
vacuolisation, 
 4/8 (50%) 
interstitial 
fibrosis 
THOM[62] 1999 UCL 
 London 
UK 
15  
(14-69) 
Case Control/ 
Quantitative 
Evaluation 
Amygdala: Lower neuronal 
densities and increased 
astrocytic densities in lateral 
nucleus of amygdala compared 
to controls 
no details No detail 
ANTONIUK[131] 1990-1999 Curitiba, 
Brazil 
20 
 (11-50 ys) 
Retrospective 
Review, PM 
Findings 
Cerebral oedema 11/20 (55%) 12/20 (60%) 
pulmonary oedema 
Pulmonary 
haemorrhage 
(1/20) 
No detail 
BLACK &  
GRAHAM[30] 
1991-1996 Glasgow,  
UK 
131  
(adults) 
Retrospective 
Review, PM 
Findings 
66%: old TBI, HS, hypoxic-
ischaemic brain injury. 
No detail No detail 
SHIELDS[80] 1996-2000 Louisville, 
USA 
70 
 (16-71 ys) 
Retrospective 32/60 (53%): old TBI (59%), 
hippocampal/cortical atrophy 
(26%), cerebellar atrophy 
(31%), VM (6%), Tumour (3%), 
cerebellar damage (57%), 
inflammation (38%) 
(81%) Pulmonary 
oedema/congestion  
 No detail 
DAVIS & 
MCGWIN[132] 
1986-2000 Jefferson 
County,  
USA 
57 
(14-77 ys) 
Retrospective, 
Case Control 
No detail No difference in 
lung weights 
compared to 
control group 
No contraction 
band necrosis in 
SUDEP group ; no 
differences in 
heart weights 
P-CODREA[133] 1998-2000 Northern 
Jutland, 
Denmark 
15 
 (17-56 ys) 
Prospective 
study, PM 
Findings/ 
Quantitative 
Evaluation  
8/15 (53%) :  old TBI, old ICH,  
FCD, Microcephaly, heterotopia 
No detail Significant foci of 
myocardial 
fibrosis 
compared to age 
matched controls 
(p=0.03) 
THOM[57] 2003 UCL,  
London 
UK 
18 
(17-69 ys) 
Case Control / 
Quantitative 
Evaluation 
Increased HSP-70
+
 neurones in 
hippocampal in SUDEP 
compared to control groups. 
Also noted in insular cortex. 
13/18 (72%) 
Pulmonary oedema  
No detail 
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ZHOU[23] 2007-2009 Maryland, 
USA 
74  
(14-63 ys) 
Retrospective 43/74 (58.1%); old TBI (13.5%), 
MCD (6.8%), cerebellar atrophy 
(5.4%), VM (4.1%), 
Hippocampal gliosis (2.7%), 
cortical/hippocampal atrophy 
(2.7%), CVA (2.7%). Tumours 
(2.7%), TS (1.4%), acute 
neuronal injury (1.4%) 
(100%) 
Pulmonary 
congestion/oedema  
(9.5%) moderate 
LVH (4.1%) mild 
coronary 
atherosclerosis 
(21.2%) myocyte 
hypertrophy  
(42.3%) 
myocardial 
fibrosis  
FEAST[89] 2012 UCL  
London 
UK 
7 
 (adults) 
Case Control / 
Quantitative 
Evaluation 
Hippocampal HIF1α expression 
in SUDEP compared to controls 
No detail No details 
RYVLIN[12] 1968-2007 Multi- 
Centre, 
Inter- 
National 
8 
 (with PM) 
Survey  5/8 (62%): Hippocampal 
atrophy (2/8), probable 
encephalitis (2/8), 
Ganglioglioma (1/8):These were 
ante-mortem diagnosis and not 
detailed or confirmed  in 
autopsy findings available 
3/8 (37%) 
Pulmonary oedema  
1/8 (12.5%) 
subendocardial 
fibrosis, 
1/8 (12.5%) 
coronary 
atherosclerosis  
THOM[31] 2016 Multi- 
centre,  
UK 
145  
(2-82 ys) 
Retrospective Neuropathology Macroscopic 
(52%), Microscopic (89%): Mild 
brain swelling (28%), MCD 
(15%), Tumour (6.8%), HS 
(21%), Old TBI (17%), CVA 
(6.9%), Cerebellar atrophy 
(41%), acute neuronal injury 
(55%) 
(68%) Pulmonary 
oedema/congestion  
No detail 
MICHALAK[56] 2017 UCL 
 London, 
UK 
28  
(18-69 ys) 
Case Control 
Study / 
Quantitative 
Evaluation 
Neuroimflammation in SUDEP: 
Brainstem reduced CD163-
positive macrophages in SUDEP 
& lower IgG in CA1 and 
parahippocampal gyrus  than 
controls 
No detail No detail 
 
Table 2. Pathology studies in SUDEP based on series with more than one case and the positive findings are 
detailed. CVA = Cerebro-vascular accident, FCD= focal cortical dysplasia, HS= hippocampal sclerosis, NOS= not 
otherwise specified, TBI = traumatic brain injury, TS = Tuberous Sclerosis, VM= vascular malformation, 
PM=post-mortem, ICH = intra cranial haemorrhage, ys = years.  Studies with details of macro and/or 
histological findings are included.  
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Likely SUDEP 
Gene 
Protein/Cellular Role Clinical Disorder(s) Expression Site(s) 
Primary cardiac genes 
   KCNQ1 
[134] 
Potassium channel KvLQT1/Kv7.1; 
ventricular repolarization 
Long QT Brain, heart, lung 
   KCNH2 
[134, 135] 
Potassium channel hERG1/Kv11.1; 
repolarization of cardiac action 
potential 
Long QT 
Epilepsy 
Brain, heart, lung 
   SCN5a 
[134, 135] 
Sodium channel, Nav1.5; rapid 
depolarizing sodium current 
underlying cardiac action potential 
upstroke 
Long QT 
Brugada 
Brain, heart, lung 
   NOS1AP 
[134] 
Cytosolic protein that binds to 
neuronal nitric oxide synthase  
Long QT Brain, heart, lung 
   RYR2 
[134, 135] 
Cardiac ryanodine receptor 2, acts 
as intracellular Ca2+ release 
channel, coupling excitation–
contraction  
Sudden cardiac death Brain, heart, lung 
    HCN4 
[134, 135] 
Hyperpolarization activated cyclic 
nucleotide gated potassium 
channel 4; slow kinetics of 
activation and inactivation, cardiac 
pacemaker role 
Brugada, Sick sinus 
rhythm 
Brain, heart, lung 
LBD3  
[136] 
Involved in protein kinase-C 
mediated signalling in striated 
muscle 
Dilated 
cardiomyopathy, 
arrhythmogenic 
ventricular dysplasia 
Heart, brain, lung 
DSC2  
[136] 
Component of intercellular 
desmosome junctions 
 
Arrhythmogenic 
ventricular dysplasia, 
cardiomyopathy 
Heart, brain, lung 
KCNE1 
[136] 
 Long QT Heart, brain, lung 
   Primary Epilepsy or Brain Gene 
   SCN1A 
[99] 
Sodium channel Nav1.1 Dravet/EE, GEFS+ Brain, heart, lung 
   SCN2A 
[137] 
Sodium channel Nav 1.2 EE Brain, heart, lung 
   SCN8A
 
[137] 
Sodium channel Nav 1.6 EE Brain, heart, lung 
   PRRT2 
[135] 
Proline-rich transmembrane 
protein 2 
Benign familial infantile 
seizures 
Brain 
   DEPDC5 
[103] 
G-protein signalling pathway. 
Component of the GATOR1 
complex which inhibits mTORC1 
pathway 
Focal epilepsy (broad 
spectrum of 
phenotypes) 
Brain, heart, lung 
   CSTB A stefin that inhibits intracellular 
thiol protease; may prevent 
protease leakage from lysosomes 
Unverricht-Lundborg 
disease 
Brain, heart, lung 
TSC2, TSC1 Hamartin (TSC1), 
Tuberin (TSC2); Downregulate the 
mTORC1 pathway 
Tuberous sclerosis 
complex 
Brain, heart, lung 
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    HCN2 
[135] 
Hyperpolarization activated cyclic 
nucleotide gated potassium 
channel 2; Contributes to 
spontaneous rhythmic activity in 
heart (sinoatrial node) and brain 
Generalized epilepsy Brain, heart, lung 
KCNT1  
[138] 
Outwardly rectifying potassium 
channel subunit 
Focal epilepsy, EE Brain, lung, heart 
Chromosomal disorders* 
   Dup15q11 
[99] 
supernumerary isodicentric 
chromosome 15; extra copies of 
UBE3A (Angelman syndrome) and 
GABRB3 (GABA receptor) 
EE; variable epilepsy 
phenotype 
UBE3A - brain, heart, 
lung 
 
GABRB3 - brain, heart, 
lung 
 
   5q14.3 deletion 
[139] 
 
Haploinsufficiency of MEF2C (role 
in myogenesis) and EFNA5 - 
receptor protein-tyrosine kinases 
involved in neurodevelopment 
Variable severity of 
epilepsy and 
neurodevelopmental 
disability  
MEF2C - brain, heart, 
lung 
 
EFNA5 - brain, heart, 
lung 
 
Table 3. Genes implicated in SUDEP. ES – epilepsy severity; EE – epileptic encephalopathy; *No animal models 
exist for these genetic disorders and with most genes, it is uncertain if the risk of SUDEP is solely accounted for 
by the severity of epilepsy and developmental delays 
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Brain 
region 
Approximate 
coronal 
level* 
/ side for 
sampling 
Rationale for sampling in  
routine POST-MORTEM examination 
in ERDs 
Evidence implicating relevance to 
SUDEP : 
Clinical / neuroimaging / 
pathological studies 
Frontal 
watershed 
regions (F1/2) 
Anterior level/ 
Both hemispheres 
 
 Assessment of recent hypoxic-ischaemic 
brain damage in watershed regions 
 Exclude unsuspected 
meningitis/encephalitis 
 
Fronto-basal 
cortex 
Anterior level/ 
Both hemispheres 
 Investigation of old or subtle TBI  Old TBI, particularly cortical contusions, 
frequent in SUDEP series (see Table 1) 
Insular cortex 
with basal 
ganglia 
Several levels/ 
Both hemispheres 
 ‘Screening’ block to exclude unsuspected 
meningitis/encephalitis, small vessel 
disease, metabolic or neurodegenerative 
process 
 Insular cortex has cardiac autonomic 
roles  
 Clinical/pathology evidence linking this 
region to SUDEP [84] 
 HSP-70 protein expression shown in 
SUDEP [57] 
Amygdala Both Hemispheres  Frequent evidence for amygdala MRI 
volume alterations and gliosis/sclerosis, 
mainly linked with TLE (recently reviewed 
in [58]) as sequel of seizures  
 Stimulation of amygdala induces apnoea  
[60, 61] 
 Loss of neurones in lateral nucleus in 
SUDEP [62] 
 Altered volume in MRI studies of SUDEP 
[63] 
Thalamus Mid Coronal level 
 
 Evidence for thalamic pathology in 
epilepsy as possible sequel of seizures 
(reviewed in [79]) 
 Role in seizure initiation and modulation 
 Altered volume in MRI studies in SUDEP 
including pulvinar nucleus [63] 
 Cardioregulatory roles 
Temporal 
cortex 
Superior and 
middle 
temporal gyrus 
Posterior level/ 
Both hemispheres 
 
 To exclude unsuspected 
meningitis/encephalitis or 
hypoxic/ischaemic brain damage 
 Exclude epilepsy related pathology 
include temporal lobe sclerosis, cortical 
dysplasia, mild malformations etc. 
 
Hippocampus Posterior or 
several levels 
(or where it 
appears 
abnormal)/ 
Both sides 
 HS frequent in TLE and other epilepsy 
syndromes 
 HS may be unilateral or bilateral  
 Specific cellular alterations support 
epilepsy mediated damage  over other 
causes (e.g. ischaemic, 
neurodegenerative) (reviewed in [34] 
 Links with cardiorespiratory regulatory 
brain regions and stimulation induces 
apnoea [60] 
 Pathology associated with SUDEP (see 
Table1) and reported in SIDS 
 Altered volume in MRI studies in SUDEP 
[63] 
Cerebellum 
cortex 
Watershed region 
(or region of 
atrophy) 
 Frequent atrophy in TLE and other 
epilepsies  
 Atrophy variably reported in SUDEP PM 
series (see Table 1) 
 Autonomic roles, including blood 
pressure regulation [140] 
Medulla Mid/high  
obex level 
 Exclude unsuspected 
inflammatory/vascular/neoplastic disease 
 Cardio-regulatory nuclei  
 Evidence from SUDEP models  [51] 
 Altered volume in MRI studies of SUDEP 
[55] 
Macroscopic 
abnormality/ 
brain lesion 
  Could pertain to cause of death or 
underlying epilepsy 
 Correlate block sampling with any 
localising Investigations during life to 
maximise detection (e.g.EEG, MRI 
findings, seizure semiology)  
 
 
Table 4. Suggested neuropathological sampling protocols for histology in the investigation of suspected SUDEP and the 
rationale. Based on recommendations from the Royal college of Pathologists autopsy series: deaths in epilepsy, issued in 
2006 (currently withdrawn for revision). The sampling strategy is a minimal approach of a set of blocks which aim to 
exclude other unsuspected pathology (not visualised macroscopically) as cause of death or epilepsy as well as disclose 
common, secondary, epilepsy-related pathologies. Such a systematic sampling protocol could facilitate research work 
between centres in SUDEP. Other desirable blocks that could be considered/bio-banked for future research include regions 
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with cardio-regulatory function including midbrain, pons (parabrachial pontine nuclei involved in respiratory 
rhythmogenesis, raphe nuclei (RN) comprising serotonergic neurons, retrotrapezoid nucleus and parafacial respiratory 
group, deep cerebellar nuclei, pulvinar, cortical blocks from cingulate, anterior frontal and more extensive blocks of insular, 
thalamus and amygdala nuclei. *Anterior coronal levels correspond to the nucleus accumbens, mid-level to the 
mammillary bodies and posterior level to the lateral geniculate nucleus. 
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